医学
抗体-药物偶联物
癌肉瘤
癌症研究
结合
拓扑异构酶
有效载荷(计算)
药品
肿瘤科
抗体
内科学
药理学
单克隆抗体
免疫学
酶
癌
生物
数学分析
生物化学
计算机网络
数学
网络数据包
计算机科学
作者
Michelle P. Greenman,Stefania Bellone,Cem Demirkiran,Tobias M.P. Hartwich,Victoria M. Ettorre,Blair C. McNamara,Namrata Sethi,Niccolò G. Santin,Luca Palmieri,Yang Yang‐Hartwich,Elena Ratner,Alessandro Davide Santin
标识
DOI:10.1016/j.ygyno.2025.06.017
摘要
Background Uterine and ovarian carcinosarcomas (CS) are rare gynecologic tumors with a high recurrence rate and poor prognosis. Datopotamab-deruxtecan (Dato-DXd) is a novel antibody-drug-conjugate (ADC) targeting TROP2. We evaluated the preclinical activity of Dato-DXd in vitro against primary and metastatic CS cell lines with various TROP2 expression and in vivo against CS xenografts in mice. Methods TROP2 expression was determined using flow-cytometry. Cells were treated with Dato-DXd and a control ADC (CTL ADC) to evaluate IC 50 values. Double-strand-DNA-breakage assay evaluated DNA damage while antibody-dependent-cell-cytotoxicity (ADCC) was evaluated using a 4-h chromium-release assay. Mice harboring CS xenografts were treated via retro-orbital Dato-DXd administration. Results TROP2 expressing CS cell lines were highly sensitive to killing induced by Dato-DXd . In contrast, low-expressing CS cell lines had no significant difference in cell cytotoxicity. Dato-DXd induced ADCC in the presence of peripheral blood lymphocytes from healthy donors. When TROP2-negative cells were admixed with TROP2-overexpressing cells, a significant bystander effect with Dato-DXd was appreciated. In vivo, mouse xenografts overexpressing TROP2 treated with Dato-DXd demonstrated tumor growth suppression and longer overall survival compared to CTL ADC-treated xenografts. Conclusions Dato-DXd is active against primary and metastatic uterine and ovarian CS overexpressing TROP2 in vitro and in vivo. Our preclinical results warrant future clinical trials for patients with advanced/recurrent gynecologic CS resistant to chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI